Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
This is an open-label, randomized, multi-site, Phase II, interventional trial designed to
evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in
anti-PD1-refractory/relapsed patients with unresectable Stage III or IV melanoma. The
contributions of BNT111 and cemiplimab will be delineated in single agent calibrator arms.
Patients in single agent calibrator arms, who experience disease progression under single
agent treatment, may be offered addition of the other compound to the ongoing treatment after